Ertapenem

Kathmandu University Medical Journal

Volumn 7, Issue 28, 2009, Pages 454-460

  Parakh, A ^a   Krishnamurthy, S ^a   Bhattacharya, Malobika ^b  

^a UNIVERSITY COLLEGE OF MEDICAL SCIENCES   (India)

^b LOK NAYAK HOSPITAL   (India)

Author keywords

Antibiotics; Carbapenems; Ertapenem

Indexed keywords

BETA LACTAMASE; CEFOTETAN; CEFTRIAXONE; CILASTATIN; ERTAPENEM; IMIPENEM; MEROPENEM; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; TIMENTIN;

ABDOMINAL INFECTION; ANAEROBIC BACTERIUM; ANTIMICROBIAL ACTIVITY; ANTIMICROBIAL THERAPY; CHILD; COLORECTAL SURGERY; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ELECTIVE SURGERY; ENDOMYOMETRITIS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GYNECOLOGIC INFECTION; HUMAN; NAUSEA; OUTPATIENT; PELVIC INFLAMMATORY DISEASE; POSTOPERATIVE COMPLICATION; PROPHYLAXIS; REVIEW; SEIZURE; SEPTIC ABORTION; SIDE EFFECT; SKIN INFECTION; SKIN STRUCTURE; SURGICAL INFECTION; THROMBOPHLEBITIS; URINARY TRACT INFECTION;

EID: 74849084620     PISSN: 18122027     EISSN: 18122078     Source Type: Journal    
DOI: 10.3126/kumj.v7i4.2774     Document Type: Review

References (27)

1. Shah PM, Issaca RD. Ertapenem, the first of a new group of carbapenem. J Antimicrob Chemother. 2003; 52: 538-42.
2. Merck and Co. [homepage in the internet]. INVAZ (Ertapenem for injection): prescribing information. Available from the URL: http://www.merck.com
3. Nicolau DP. Carbapenems: a potent class of antibiotics. Expert Opin Pharmacother. 2008; 9:23-37.
4. Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, et al. Comparative review of the carbapenems. Drugs. 2007; 67:1027-52.
5. Livermore DM, Carter MW, Bagel S, Wiedemann B, Baquero F, Loza E, et al. In vitro activities of Ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrob Agents Chemother. 2001; 45:1860-7.
6. Nix DE, Majumdar AK, DiNubile MJ. Pharmacokinetics and pharmacodynamics of Ertapenem: an overview for clinicians. J Antimicrob Chemother. 2004; 53 Suppl 2:23-8.
7. Tomera KM, Burdmann EA, Reyna OG. Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multi-center study. Antimicrob. Agents Chemother. 2002; 46:2895-900.
8. Jimenez-Cruz F, Jasovich A, Cajigas J. A prospective, multicenter, randomized, double blind study comparing Ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults. Urology. 2002; 60:16-22.
9. Vetter N, Cambronero-Hernandez E, Rohlf J. A prospective, randomized, double-blind multicenter comparison of parenteral Ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia. Clin. Ther. 2002; 24:1770-85.
10. Ortiz-Ruiz G, Caballero-Lopez J, Friedland IR. A study evaluating the efficacy, safety, and tolerability of Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. Clin Infect Dis. 2002; 34:1076-83.
11. Ortiz-RuizG, Vetter N, Isaacs R. Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicenter randomized, double blind studies. J Antimicrob Chemother. 2004; 53: :59-66.
12. Graham DR, Lucasti C, Malafaia O et al.: Ertapenem once daily versus piperacillin/tazobactam four-times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double blind multi-center study. Clin Inf Dis. 2002; 34:1560-8.
13. Solomkin JS, Yellin AE, Rotstein OD. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intra-abdominal infections:results of a double-blind, randomized comparative phase III trial. Ann Surg. 2003; 237:235-45.
14. De La Pena AS, Asperger W, Kockerling F. Efficacy and safety of Ertapenem versus piperacillin/tazobactam for the treatment of intra-abdominal infections requiring surgical intervention. J Gastrointest Surg. 2006; 10:567-74.
15. Yellin AE, Hassett JM, Fernandez A. Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections in adults. Int J Antimicrob Agents. 2002: 20:165-73.
16. Roy S, Higareda I, Angel-Muller E. Ertapenem once-a-day versus piperacillin/tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multi-center, randomized, double-blind study. Infect Dis Obstet Gynecol. 2003; 11:27-37.
17. Lipsky BA, Armstrong DG, Citron DM. Ertapenem versus piperacillin/ tazobactam for diabetic foot infections (SIDESTEP): prospective,randomized, controlled, double-blind, multi-center trial. Lancet. 2005; 366:1695-703.
18. Itani KM, Jensen EH, Finn TS, Tomassini JE, Abramson MA. Effect of Body Mass Index and Ertapenem versus Cefotetan Prophylaxis on Surgical Site Infection in Elective Colorectal Surgery. Surg Infect (Larchmt) 2008; 9:131-137.
19. Gesser RM, Carrol KA, Teppler H. Efficacy of Ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data. J Antimicrob Chemother. 2003; 51:1253-60.
20. Tellado J, Woods GL, Gesser RM. Ertapenem versus piperacillin/tazobactam for treatment of mixed anaerobic complicated intra-abdominal, complicated skin and skin-structure, and acute pelvic infections. Surg. Infect. 2002; 3:303-14.
21. Solomkin J, Teppler H, Graham DR. Treatment of polymicrobial infections: post hoc analysis of three trials comparing Ertapenem and piperacillin/ tazobactam. J. Antimicrob Chemother. 2004; 53:51-7.
22. Yellin AE, Johnson J, Higareda I, Congeni BL, Arrieta AC, Fernsler D, West J, Gesser R. Ertapenem or ticarcillin/clavulanate for the treatment of intra-abdominal infections or acute pelvic infections in pediatric patients. Am J Surg. 2007; 194:367-74.
23. Arguedas A, Wang J, Snyder T. Safety and efficacy in a double-blind study of Ertapenem versus ceftriaxone in pediatric patients with complicated urinary tract infections, community acquired pneumonia, or skin and soft tissue infections. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA 2005.
24. Yakovlev SV, Stratchounski LS, Woods GL, Adeyi B, McCarroll KA, Ginanni JA, Friedland IR, Wood CA, DiNubile MJ. Ertapenem versus cefepime for initial empirical treatment of pneumonia acquired in skilled-care facilities or in hospitals outside the intensive care unit. Eur J Clin Microbiol Infect Dis. 2006; 25:633-41.
25. Boselli E, Breilh D, Saux MC, Gordien JB, Allaouchiche B. Pharmacokinetics and lung concentrations of Ertapenem in patients with ventilator-associated pneumonia. Intensive Care Med. 2006; 32: 2059-62.
26. Bassetti M, Righi E, Fasce R, Molinari MP, Rosso R, Di Biagio A, et al. Efficacy of Ertapenem in the treatment of early ventilator-associated pneumonia caused by extended-spectrum beta-lactamase-producing organisms in an intensive care unit. J Antimicrob Chemother. 2007; 60: 433-5.
27. Teppler H, Gesser RM, Friedland IR, Woods GL, Meibohm A, Herman G, Mistry G, Isaacs R. Safety and tolerability of Ertapenem. J Antimicrob Chemother. 2004; 53 Suppl 2: 75-81.